Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 143,479 |
|
|||||
| News | - | ||||||
| Day High | 12.16 | Low High |
|||||
| Day Low | 11.6043 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Neumora Therapeutics Inc | NMRA | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.51 | 4.21% | 12.61 | 15:21:17 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 12.10 | 11.6043 | 12.16 | 11.77 | 12.10 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,237 | 143,479 | US$ 11.92 | US$ 1,710,858 | - | 9.35 - 17.69 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:21:16 | 95 | US$ 12.79 | USD |
Neumora Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 1.93B | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Neumora Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/28/2023 | 15:21 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/27/2023 | 06:00 | GlobeNewswire Inc. | Neumora Therapeutics Announces NMRA-266 IND Clearance and.. |
| 11/01/2023 | 15:05 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 11/01/2023 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/01/2023 | 06:00 | GlobeNewswire Inc. | Neumora Therapeutics Reports Third Quarter 2023 Financial.. |
| 10/30/2023 | 06:00 | GlobeNewswire Inc. | Neumora Therapeutics to Participate in Upcoming Conferences.. |
| 10/10/2023 | 06:00 | GlobeNewswire Inc. | Neumora Therapeutics Announces Appointment of Robert Lenz,.. |
| 9/14/2023 | 19:49 | GlobeNewswire Inc. | Neumora Therapeutics Announces Pricing of Initial Public.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NMRA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 12.02 | 12.9999 | 10.00 | 12.06 | 307,911 | 0.59 | 4.91% |
| 1 Month | 12.09 | 12.9999 | 10.00 | 11.76 | 216,868 | 0.52 | 4.3% |
| 3 Months | 16.50 | 17.69 | 9.35 | 11.92 | 345,888 | -3.89 | -23.58% |
| 6 Months | 16.50 | 17.69 | 9.35 | 11.92 | 345,888 | -3.89 | -23.58% |
| 1 Year | 16.50 | 17.69 | 9.35 | 11.92 | 345,888 | -3.89 | -23.58% |
| 3 Years | 16.50 | 17.69 | 9.35 | 11.92 | 345,888 | -3.89 | -23.58% |
| 5 Years | 16.50 | 17.69 | 9.35 | 11.92 | 345,888 | -3.89 | -23.58% |
Neumora Therapeutics Description
| Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. |
